interesting comments. VYVGART has been in use for about 2 years for MG patients. It is a short period in the history of the drug but nevertheless it is now been recommended for CIDP patients too by FDA. Argnex investors seems to like it to , SP moving up 50%+.
Considering the above CSL revenue has to be impacted in long run, isn’t? Unless as you say CSL gets something new out of Momenta
acquisition. Are there any updates on Momenta progress?
interesting comments. VYVGART has been in use for about 2 years...
-
- There are more pages in this discussion • 158 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$300.58 |
Change
-1.210(0.40%) |
Mkt cap ! $145.5B | |||
| Open | High | Low | Value | Volume |
| $300.74 | $300.99 | $298.81 | $240.1M | 820.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $300.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $300.59 | 836 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| CSL (ASX) Chart |